19:01 , Oct 26, 2018 |  BC Week In Review  |  Company News

AstraZeneca gets rights, options to Innate immuno-oncology therapies

AstraZeneca plc (LSE:AZN; NYSE:AZN) expanded its next generation immuno-oncology pipeline on Oct. 23, gaining rights and options to a basket of therapies from Innate Pharma S.A. (Euronext:IPH). In return, Innate gained U.S. and European commercialization...
23:17 , Oct 23, 2018 |  BC Extra  |  Company News

AstraZeneca gets rights, options to basket of next-gen immuno-oncology therapies from Innate

AstraZeneca plc (LSE:AZN; NYSE:AZN) expanded its next generation immuno-oncology pipeline on Tuesday, gaining rights and options to a basket of therapies from Innate Pharma S.A. (Euronext:IPH). In return, Innate gained U.S. and European commercialization rights...
18:14 , Oct 19, 2018 |  BC Week In Review  |  Financial News

PhaseBio, Osmotica price NASDAQ IPOs well below range

Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc (NASDAQ:OSMT) each priced IPOs well below their proposed ranges late Oct. 17. PhaseBio trading ended flat at $5 on Oct....
05:38 , Oct 18, 2018 |  BC Extra  |  Financial News

PhaseBio, Osmotica price IPOs well below range

Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc (NASDAQ:OSMT) each priced IPOs well below their proposed ranges late Wednesday. PhaseBio trading ended flat at $5 on Thursday, while...
20:31 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

PhaseBio's PB2452 reverses antiplatelet activity of Brilinta in Phase I

PhaseBio Pharmaceuticals Inc. (Malvern, Pa.) said PB2452 (formerly MEDI2452) rapidly and completely reversed the antiplatelet activity of cardiovascular drug Brilinta ticagrelor from AstraZeneca plc (LSE:AZN; NYSE:AZN) in a Phase I trial. The company is developing...
18:42 , Sep 28, 2018 |  BC Week In Review  |  Financial News

PhaseBio files for $86.3M NASDAQ IPO

PhaseBio Pharmaceuticals Inc. (Malvern, Pa.) proposed on Sept. 21 to raise $86.3 million in an IPO on NASDAQ underwritten by Citigroup, Cowen, Stifel and Needham. On Sept. 7, PhaseBio raised $34 million in a series...
16:41 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

AZ's anifrolumab misses in Phase III for lupus

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said anifrolumab (formerly MEDI-546) missed the primary endpoint in the Phase III TULIP 1 trial to treat systemic lupus erythematosus (SLE). Compared with placebo, anifrolumab failed...
18:15 , Aug 31, 2018 |  BC Extra  |  Clinical News

AZ's anifrolumab misses in Phase III for lupus

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said anifrolumab (formerly MEDI-546) missed the primary endpoint in the Phase III TULIP 1 trial to treat systemic lupus erythematosus (SLE). Compared with placebo, anifrolumab failed...
22:32 , Aug 16, 2018 |  BC Extra  |  Company News

Management tracks: Achillion, Navidea

Rare disease company Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) hired Anthony Gibney as EVP and CBO. He was managing director and co-head of the biotechnology investment banking team at Leerink Partners. Immunotherapy company Navidea Biopharmaceuticals Inc. (NYSE-A:NAVB;...
22:04 , Jul 19, 2018 |  BC Innovations  |  Tools & Techniques

Immunotherapy Matchmaking

MD Anderson Cancer Center is using its access to patient samples to inject more rationality into decisions about which therapies should be paired with checkpoint inhibitors, and how to optimize the combos. The goal is...